356 related articles for article (PubMed ID: 26653339)
21. Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Sanmartín-Fernández M; Marzal-Martín D
Clin Appl Thromb Hemost; 2017 Oct; 23(7):711-724. PubMed ID: 27624737
[TBL] [Abstract][Full Text] [Related]
22. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Chan YH; Lee HF; Wang CL; Chang SH; Yeh CH; Chao TF; Yeh YH; Chen SA; Kuo CT
J Am Heart Assoc; 2019 Nov; 8(21):e013053. PubMed ID: 31623498
[TBL] [Abstract][Full Text] [Related]
23. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Sep; 128(11):e172-3. PubMed ID: 24019452
[No Abstract] [Full Text] [Related]
24. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
25. Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
Apostolakis S; Lane DA; Banerjee A
Circulation; 2013 Sep; 128(11):e171. PubMed ID: 24019451
[No Abstract] [Full Text] [Related]
26. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation.
Barón-Esquivias G; Fernández-Avilés F; Atienza F; Pastor Pueyo P; Toro R; Sanmartín Fernández M
Expert Rev Cardiovasc Ther; 2015 Apr; 13(4):341-53. PubMed ID: 25797900
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Laube ES; Yu A; Gupta D; Miao Y; Samedy P; Wills J; Harnicar S; Soff GA; Mantha S
Am J Cardiol; 2017 Jul; 120(2):213-217. PubMed ID: 28549819
[TBL] [Abstract][Full Text] [Related]
28. Rivaroxaban: searching the integral vascular protection.
Barrios V; Almendro-Delia M; Facila L; Garcia-Moll X; Mazón P; Camafort M; Cepeda JM; Mediavilla Garcia JD; Pose Reino A; Suarez Fernandez C
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):719-728. PubMed ID: 29965791
[TBL] [Abstract][Full Text] [Related]
29. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; van Eickels M; Turpie AG
Vasc Health Risk Manag; 2014; 10():425-34. PubMed ID: 25083135
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.
Althunian TA; de Boer A; Groenwold RHH; Rengerink KO; Souverein PC; Klungel OH
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1263-1272. PubMed ID: 32537897
[TBL] [Abstract][Full Text] [Related]
31. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Vimalesvaran K; Dockrill SJ; Gorog DA
Vasc Health Risk Manag; 2018; 14():13-21. PubMed ID: 29391805
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
[TBL] [Abstract][Full Text] [Related]
33. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Steinberg BA; Hellkamp AS; Lokhnygina Y; Patel MR; Breithardt G; Hankey GJ; Becker RC; Singer DE; Halperin JL; Hacke W; Nessel CC; Berkowitz SD; Mahaffey KW; Fox KA; Califf RM; Piccini JP;
Eur Heart J; 2015 Feb; 36(5):288-96. PubMed ID: 25209598
[TBL] [Abstract][Full Text] [Related]
34. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
Breithardt G; Baumgartner H; Berkowitz SD; Hellkamp AS; Piccini JP; Lokhnygina Y; Halperin JL; Singer DE; Hankey GJ; Hacke W; Becker RC; Nessel CC; Mahaffey KW; Califf RM; Fox KA; Patel MR;
Heart; 2016 Jul; 102(13):1036-43. PubMed ID: 26888572
[TBL] [Abstract][Full Text] [Related]
35. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial.
Kochar A; Hellkamp AS; Lokhnygina Y; Jones WS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Singer DE; Piccini JP; Patel MR
Clin Cardiol; 2018 Jan; 41(1):39-45. PubMed ID: 29389037
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.
Barón-Esquivias G; Marín F; Sanmartín Fernandez M
Expert Rev Cardiovasc Ther; 2017 May; 15(5):403-413. PubMed ID: 28319424
[TBL] [Abstract][Full Text] [Related]
38. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban.
Barrios V; Górriz JL
J Comp Eff Res; 2015 Nov; 4(6):651-64. PubMed ID: 26388302
[TBL] [Abstract][Full Text] [Related]
39. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.
Cappato R; Marchlinski FE; Hohnloser SH; Naccarelli GV; Xiang J; Wilber DJ; Ma CS; Hess S; Wells DS; Juang G; Vijgen J; Hügl BJ; Balasubramaniam R; De Chillou C; Davies DW; Fields LE; Natale A;
Eur Heart J; 2015 Jul; 36(28):1805-11. PubMed ID: 25975659
[TBL] [Abstract][Full Text] [Related]
40. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
